JP2023513350A - がんまたは腫瘍の治療の方法 - Google Patents

がんまたは腫瘍の治療の方法 Download PDF

Info

Publication number
JP2023513350A
JP2023513350A JP2022548836A JP2022548836A JP2023513350A JP 2023513350 A JP2023513350 A JP 2023513350A JP 2022548836 A JP2022548836 A JP 2022548836A JP 2022548836 A JP2022548836 A JP 2022548836A JP 2023513350 A JP2023513350 A JP 2023513350A
Authority
JP
Japan
Prior art keywords
seq
cancer
cells
sequence
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513350A5 (https=
Inventor
ジョナサン パンフリー，ニコラス
Original Assignee
アダプティミューン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダプティミューン・リミテッド filed Critical アダプティミューン・リミテッド
Publication of JP2023513350A publication Critical patent/JP2023513350A/ja
Publication of JP2023513350A5 publication Critical patent/JP2023513350A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4265—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022548836A 2020-02-14 2021-02-12 がんまたは腫瘍の治療の方法 Pending JP2023513350A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062976493P 2020-02-14 2020-02-14
US62/976,493 2020-02-14
PCT/GB2021/050341 WO2021161032A1 (en) 2020-02-14 2021-02-12 Method of treatment of cancer or tumour

Publications (2)

Publication Number Publication Date
JP2023513350A true JP2023513350A (ja) 2023-03-30
JP2023513350A5 JP2023513350A5 (https=) 2024-02-21

Family

ID=74759208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548836A Pending JP2023513350A (ja) 2020-02-14 2021-02-12 がんまたは腫瘍の治療の方法

Country Status (7)

Country Link
US (1) US20230390334A1 (https=)
EP (1) EP4103284A1 (https=)
JP (1) JP2023513350A (https=)
CN (1) CN115087489A (https=)
AU (1) AU2021219334A1 (https=)
CA (1) CA3167436A1 (https=)
WO (1) WO2021161032A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525537A (ja) * 2013-07-26 2016-08-25 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔ細胞レセプター
WO2020024915A1 (zh) * 2018-07-30 2020-02-06 广东香雪精准医疗技术有限公司 一种识别afp抗原的t细胞受体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
JP7037577B2 (ja) * 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525537A (ja) * 2013-07-26 2016-08-25 アダプティミューネ リミテッドＡｄａｐｔｉｍｍｕｎｅ Ｌｉｍｉｔｅｄ Ｔ細胞レセプター
WO2020024915A1 (zh) * 2018-07-30 2020-02-06 广东香雪精准医疗技术有限公司 一种识别afp抗原的t细胞受体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ARCHIVE: NCT03132792, [2025/1/29検索]，2019年1月 22日, JPN6025005039, ISSN: 0005682910 *
HEPATOLOGY, vol. 69, no. 5, JPN6025005037, 2019, pages 2061 - 2075, ISSN: 0005682909 *
J. IMMUNOTHER., vol. 31, [3], JPN6018019544, 2008, pages 246 - 253, ISSN: 0005530005 *
TUMOR BIOL, vol. 37, JPN6025005038, 2016, pages 799 - 806, ISSN: 0005530004 *

Also Published As

Publication number Publication date
AU2021219334A1 (en) 2022-09-01
CA3167436A1 (en) 2021-08-19
EP4103284A1 (en) 2022-12-21
US20230390334A1 (en) 2023-12-07
CN115087489A (zh) 2022-09-20
WO2021161032A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
Cai et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
JP2023526259A (ja) がんまたは腫瘍の治療の方法
WO2022115946A1 (en) Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
JP2023528206A (ja) 癌または腫瘍の治療方法
KR20210049814A (ko) Cd80 세포외 도메인 fc 융합 단백질 투약 요법
US20220370559A1 (en) Method of treatment of cancer or tumour
JP2023513350A (ja) がんまたは腫瘍の治療の方法
IL302321A (en) IL-2/IL-15RBY agonist for the treatment of squamous cell carcinoma
CN117545771A (zh) 细胞免疫治疗的应用
US20230398185A1 (en) Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
JP2025530186A (ja) 胃食道がんの治療において使用するための改変ｔ細胞
WO2023235479A1 (en) Compositions and methods for treating cancer
JP2025530188A (ja) 膀胱がんの治療において使用するための改変ｔ細胞
JP2025530187A (ja) 頭頚部がんの治療において使用するための改変ｔ細胞
BR122020024818B1 (pt) Molécula de ácido nucleico isolada, molécula polipeptídica isolada, molécula de car isolada, domínio de ligação anti-egfrviii, vetor, método para produção de uma célula e para gerar uma população de células modificadas por rna, e uso de uma quantidade eficaz de uma célula que expressa uma molécula de car

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909